Company
Quince Therapeutics, Inc. (QNCX)
Standardized SEC financial data for Quince Therapeutics, Inc. — income statement, balance sheet, cash flow and 40+ ratios, as a clean JSON API. CIK 0001662774 · NASDAQ · Biological Products, (No Diagnostic Substances).
Return on equity
235.1%
Free cash flow
-$41.8M
Debt / equity
-0.51×
Current ratio
0.53×
EPS (diluted)
$-1.68
Income statement
| USD | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| R&D expense | $61.3M | $60.8M | $25.2M | $9.4M | $18.6M | $35.4M |
| SG&A expense |
Balance sheet
| USD | FY2021 | FY2022 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $106.8M | — | $90.2M | $75.1M | $40.8M | $17.8M |
| Total current assets |
Cash flow
| USD | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$50.8M | -$62.9M | -$44.0M | -$18.3M | -$31.9M | -$41.4M |
| Capital expenditures |
Get QNCX data via API
# JSON
curl https://sec-financial-api-production.up.railway.app/v1/company/QNCX/financials \
-H "X-API-Key: YOUR_KEY"
# CSV export (income / balance / cash-flow)
curl "https://sec-financial-api-production.up.railway.app/v1/company/QNCX/income-statement?format=csv" \
-H "X-API-Key: YOUR_KEY"